| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $191.6M | +3417.3% |
| Cost of Revenue | $12.6M | +2873.9% |
| R&D Expense | $200.5M | +33.2% |
| SG&A Expense | $256.7M | +29.9% |
| Operating Income | -$278.1M | +18.9% |
| Net Income | -$258.1M | +20.6% |
| EPS (Basic) | -$3.48 | +32.4% |
| EPS (Diluted) | -$3.48 | +32.4% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $69.8M | -60.4% |
| Accounts Receivable | $46.2M | +679.7% |
| Inventory | $10.2M | +229.1% |
| Current Assets | $380.5M | -24.0% |
| Total Assets | $587.3M | -19.1% |
| Current Liabilities | $100.0M | +27.9% |
| Total Liabilities | $106.2M | +6.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$175.6M | +21.2% |
| Capital Expenditures | $4.5M | -39.7% |
| Investing Cash Flow | $64.5M | +85.7% |
| Financing Cash Flow | $4.8M | -98.4% |
| Free Cash Flow | -$180.1M | +21.8% |
| Stockholders' Equity |
| $481.1M |
| -23.2% |